Looking to understand why some brain tumours with a specific mutation can start to reject drugs commonly used to treat them, CU Cancer Center member Jean Mulcahy Levy, MD, led researchers from institutions around the country — including several from the University of Colorado School of Medicine — to study samples of brain tumours before and after being treated with the drug.
The study looked specifically at brain tumours called gliomas that have the BRAF mutation, which occur in children and young adults.
The same mutation happens in adult melanoma, and researchers several years ago developed a medication to treat the mutation in melanoma that also can be used to treat BRAF-mutated gliomas.
“It’s a rare mutation, but it’s one of the first mutations that had a targeted medicine we could use,” Levy says. “They had a large population and developed the targeted therapies, and that allowed us to use those therapies in our brain tumour patients.”
The targeted therapy eliminates the need for chemotherapy in many patients with BRAF-mutated gliomas — not to mention it can help eliminate seizures that can occur in patients with the mutation.
However, the new challenge is that some patients develop a resistance to the medicine, eventually causing their tumours to come back. Levy and her team set out to find out what was causing the resistance, and how they could stop it from occurring.
“We collected samples of patient brain tumours that were before treatment with the targeted medicine and after treatment with the targeted medicine, which is much more difficult in brain tumours,” Levy says of the research that was published in Clinical Cancer Research.
“If you think about melanoma, they can do serial biopsies because the lesions are on the skin and easy to get to. But getting the samples from the brain are much harder.
So, we developed a collaboration that started here at CU School of Medicine, in my lab, and then we incorporated researchers from the University of California San Francisco, New York University and Johns Hopkins, and that allowed us to create a collaboration and collect 14 patient samples of pre-treatment and post-treatment.
We were able to reach out to other institutions, like Valley Children’s and Oregon Health Science University, to get their samples as well.”
Through deep genetic analysis of the tumours, including RNA sequencing and whole genome sequencing, the researchers found additional mutations that can create resistance to the targeted therapies.
Some have been described in other diseases, such as melanoma, but other mutations had never been discovered in either type of tumour before.
“It just goes to show that brain tumours may develop different resistance mechanisms from other kinds of cancers that are treated with these drugs,” Levy says. “We can’t just rely on, ‘Well, melanoma does this, so brain tumours probably do too.’
We need to be sure that we’re specifically studying brain tumours, because they’re a very different kind of disease.”
Levy and her fellow researchers are now in the process of following up on their findings, investigating new potential treatments or combination therapies that could help combat drug resistance in BRAF-mutated gliomas. Levy already is conducting a paediatric clinical trial looking for ways to reverse the resistance.
“The work we’re doing now to follow up on our genetic findings will hopefully find other additional medicines or combinations that can be used,” she says. “Cancer, at its baseline, is very smart. And it’s very rare to have any kind of tumour that you can treat with a single medication.
The ultimate goal is to find the right combination of medicines that can treat this cancer and then either prevent resistance or reverse resistance, with the least amount of complications.”
Once that combination is found, Levy says, researchers will run more clinical trials — adult and paediatric — to test its effectiveness. Her hope is that eventually, patients with this specific type of glioma won’t have to worry about recurrence or resistance.
“If we’re not focused on developing the next step in therapy, these patients will develop resistance, and then they’ll come back to us and we won’t have anything to offer them,” she says. “We need to be forward-thinking and be ready for the next therapy that has to happen for these patients.”
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.